logo-loader
viewAmphion Innovations PLC

Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio.

Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s shares.

Amphion owns 14.1% of Motif Bio.

Morgan says he continues to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development.

Quick facts: Amphion Innovations PLC

Price: 0.15 GBX

AIM:AMP
Market: AIM
Market Cap: £314.96 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amphion Innovations chief on m2m merger move

Richard Morgan, director at Amphion Innovations (LON:AMP), says the move to merge partner company m2m solutions with a private firm will result in array of products under one brand, serving the multi-billion dollar MRI marketplace in the US and Europe. m2m Imaging Corp. specialises in...

on 5/11/15

2 min read